{"id":"belimumab-injection-benlysta","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Bronchitis"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Belimumab binds to soluble BLyS (also known as BAFF), a cytokine essential for B cell survival and differentiation. By neutralizing BLyS, the drug decreases the survival of autoreactive B cells and plasma cells, leading to reduced production of pathogenic autoantibodies and immune complex formation that drive lupus pathology.","oneSentence":"Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in systemic lupus erythematosus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:40.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE) in patients with active disease despite standard therapy"},{"name":"Lupus nephritis"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Belimumab Injection [Benlysta]","genericName":"Belimumab Injection [Benlysta]","companyName":"National University Hospital, Singapore","companyId":"national-university-hospital-singapore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in systemic lupus erythematosus. Used for Systemic lupus erythematosus (SLE) in patients with active disease despite standard therapy, Lupus nephritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}